Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting

Health Policy

Volumn 65, Issue 3, 2003, Pages 261-267

  Torti, Carlo ^a   Casari, Salvatore ^a   Palvarini, Loredana ^a   Quiros Roldan, Eugenia ^a   Moretti, Francesca ^a   Leone, Luigi ^b   Patroni, Andrea ^a   Castelli, Francesco ^a   Ripamonti, Diego ^a   Tramarin, Andrea ^c   Carosi, Giampiero ^a   El Hamad, Issa ^d   Pan, Angelo ^d   Paraninfo, Giuseppe ^d   Tomasoni, Lina ^d   Pezzoli, Chiara ^d   Ucceli, Cristina ^d   Agosti, Fiorenza ^d  

^a UNIVERSITY OF BRESCIA   (Italy)

^b SPEDALI CIVILI   (Italy)

^c Department of Medical Oncology   (Italy)

^d NONE

Author keywords

HAART; Health resource; Italy

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CONSULTATION; DAY CARE; DRUG COST; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MAJOR CLINICAL STUDY; OUTPATIENT; POPULATION RESEARCH; PRESCRIPTION;

EID: 0043163830     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8510(03)00002-2     Document Type: Article

References (19)

1. Palella F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine. 338:1998;853-860.
2. Sindrome da Immunodeficienza Acquisita (AIDS) in Italia. Aggiornamento dei casi notificati al 31 dicembre 2000. Website http://www.simi.iss.it/aids. htm (accessed 28th February 2001).
3. Torres R.A., Barr M. Impact of combination therapy for HIV infection on inpatient census. New England Journal of Medicine. 336:1997;1531-1532.
4. Mouton Y., Alfandair S., Valette M., et al. Impact of protease inhibitors on AIDS-defining events and hospitalisation in 10 French AIDS centers. AIDS. 11:1997;101-105.
5. 3). HIV Clinical Trials. 1:2000;9-16.
6. Freedberg K.A., Losina E., Weinstein M.C., et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. New England Journal of Medicine. 344:2001;824-831.
7. Sendi P.P., Bucher H.C., Harr T., et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS. 13:1999;1115-1122.
8. Velasco M., Gomez A., Fernandez C., et al. Economic impact of HIV protease inhibitor therapy in the global use of health-care resources. HIV Medicine. 1:2000;246-251.
9. Messori A., Trippli S., Valani M. The cost effectiveness of antiretroviral therapy for HIV disease. New England Journal of Medicine. 345:2001;68.
10. Laurence J. The cost effectiveness of antiretroviral therapy for HIV disease. New England Journal of Medicine. 345:2001;68.
11. Centro Operativo AIDS (COA) dell'Istituto Superiore di Sanità. Aggiornamento dei casi di AIDS notificati in Italia al 30 giugno 1999. Notiziario dell'Istituto Superiore di Sanità 2000; 13: 1-11.
12. All-patient Diagnosis Related Groups (AP-DRGs). 3M Health Information Systems. Version 12.0. New York State Department of Health, Division of Health Care Financing (DHCF).
13. Rousseau M.N., Vergne L., Montes B., et al. Pattern of resistance mutations to antiretroviral drugs in extensively treated HIV-1 infected patients with failure of highly active antiretroviral therapy. Journal of Acquired Immuno Deficiency Syndrome. 26:2001;36-43.
14. Deeks S, Barbour J, Grant R, Martin J. Incidence and predictors of clinical progression among HIV-infected patients experiencing virologic failure of protease inhibitor based regimens [abstract no. 428]. Eighth Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4-8; Chicago, IL.
15. Carpenter C.C., Fischl M.A., Hammer S.M., et al. Antiretroviral therapy for HIV infection in : updated recommendations of the International AIDS Society - USA panel. Journal of American Medical Association. 280:1998;76-86.
16. Staszewski S., Morales-Ramirez J., Tashima K.T., et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. New England Journal of Medicine. 341:1999;1865-1873.
17. Moore R.D. Cost effectiveness of combination HIV therapy. 3 years later. Pharmacoeconomics. 17:2000;325-330.
18. Guidelines for the use of antiretroviral agents in HIV-inected adults and adolescents. February 5. HIV Clinical Trials. 2:2001;227-306.
19. Sendi P., Palmer A.J., Gafni A., Battegay M. Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection. Pharmacoeconomics. 19:2001;709-713.